Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04764825
Other study ID # 89456049
Secondary ID 2020-004826-47
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 26, 2021
Est. completion date May 1, 2024

Study information

Verified date April 2023
Source University of Aarhus
Contact Camilla G Uhrbrand, MD
Phone 0045 23956082
Email camgaa@rm.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective double-blind, randomized controlled trial investigating the effect of a single-dose of intraoperative methadone in patients undergoing spinal fusion.


Description:

During early recovery after surgery, intravenous opioids are typically administered to control the pain, either as intermittent bolus administration by nursing staff or by a patient-controlled analgesia device. Unfortunately, repeated doses or boluses of shorter-acting opioids, such as morphine, oxycodone and fentanyl, result in fluctuating blood concentrations, with the inherent risk of only relatively brief periods of adequate pain relief. Moreover, the use of shorter-acting opioids increases the risk of opioid-associated side effects, such as sedation, nausea and vomiting. An alternative approach to the postoperative use of shorter-acting opioids is therefore called for. In this respect, methadone is an opioid with unique pharmacological properties that may be advantageous when applied intraoperatively. A single-dose of this long acting opioid could provide a stable analgesia and potentially reduce the need for shorter-acting opioids Method: 150 patients will be included in an investigator-initiated, prospective, randomised, double-blind, controlled trial with three arms: intervention arm 1 (methadone administered at induction 0.15-0.2 mg/kg ideal body weight), Intervention arm 2 (methadone administered in the end of surgery 0.15-0.2 mg/kg ideal body weight), Control arm (morphine administered in the end of surgery 0.15-0.2 mg/kg ideal body weight). The study will be GCP-monitored, and is approved by the Danish Health and Medicines Authority (2020103115) and the Central Denmark Region Committees on Health Research Ethics (1-10-72-278-20). Objective The aim of this study is to investigate the effect of a single dose of intravenous intraoperative methadone on postoperative opioid consumption, pain and side effects in patients scheduled for spinal fusion surgery. A single dose of intravenous intraoperative morphine will be used as an active comparator. Hypothesis - Intravenous perioperative methadone reduces opioid consumption (oral cumulative equivalent dose) by 50% during the first 24 postoperative hours compared to intravenous morphine(primary outcome). - Methadone reduces opioid consumption the first 6 postoperative hours compared to intravenous morphine - Methadone reduces pain in the affected areas at rest and during coughing(1-72 hours after extubation) compared to intravenous morphine - Methadone increases patient satisfaction with pain management during the first 24 postoperative hours compared to intravenous morphine on a Numerical Rating Scale (NRS) from 0 to 10, where 0 is unsatisfied and 10 is satisfied - The effects of methadone is attenuated when administered prior to surgical incision compared to administration in the end of surgery - The frequency of opioid-related side effects is similar in the groups compared.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date May 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - All patients (=18 years =85) scheduled for elective spinal fusion surgery are screened for inclusion. Exclusion Criteria: - Allergy to study drugs - American Society of Anaesthesiologists (ASA) physical status IV or V - Prolonged QTc-interval assessed by electrocardiogram(> 440 milliseconds) - Inability to provide informed consent - Severe respiratory insufficiency(Oxygen treatment at home) - Known or clinical signs of heart failure (Ejection Fraction <30%) - Acute alcohol intoxication/delirium tremens - Known or clinical signs of increased intracranial pressure - Acute liver disease - Acute abdominal pain - Known or clinical signs of severe liver dysfunction (cirrhosis, inflammation/hepatitis or liver malignancies) - Known or clinical signs of severe kidney insufficiency(eGFR<30) - Pregnancy: women of childbearing potential will be tested with serum-HCG prior to surgery, unless the woman is using a birth control method that may be considered as highly effective (based on CTFG 'recommendations related to contraception and pregnancy testing in clinical trials'). Women of childbearing potential is defined as women between menarche and post-menopausal, unless permanently steril. Post-menopausal is defined as no menses for 12 months without alternative medical cause. - Breastfeeding mothers - Existing treatment with a high risk of QTc-interval prolongation - Existing treatment with opioids (at least the last 7days) exceeding 60 mg morphine equivalents daily - Planned postoperative treatment with epidural analgesics and/or ketamine infusion - Treatment with rifampicin - Spinal fusion surgery over >4vertebral levels - Spinal fusion surgery due to malignant disease

Study Design


Intervention

Drug:
Methadone
The dosage administered differ in regards to age and tolerance to opioids: 0.2 mg/kg: all patients <65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily. 0.15 mg/kg: Opioid naive patients > 65 years of age.
Morphine
The dosage administered differ in regards to age and tolerance to opioids: 0.2 mg/kg: all patients <65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily. 0.15 mg/kg: Opioid naive patients > 65 years of age.

Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus

Sponsors (1)

Lead Sponsor Collaborator
Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Opioid consumption (mean cumulative MME) Opioid consumption within the first 6 hours after extubation 6 hours
Primary Opioid consumption (mean cumulative MME) Opioid consumption within the first 24 hours after extubation 24 hours
Secondary Pain intensity (NRS, 0-10) at rest and coughing Pain intensity from 0-10 in the affected area at when patient is at rest and coughing at the hours: 1, 3, 6, 24, 48 and 72 after extubation 1-72 hours
Secondary Patient satisfaction with pain management Satisfaction with pain management, measured from 0-10, 24 hours following extubation 24 hours
Secondary Nausea and/or vomiting (PONV) Nausea and/or vomiting (PONV) on a 4 point Likert scale (none/mild/moderate/severe) at 6 and 24 hours. 6 - 24 hours
Secondary Readiness to discharge Time from arrival to readiness for discharge from PACU(hours and minutes), 2-24 hours
Secondary Level of sedation Level of sedation at observation in the PACU (Ramsay Sedation Scale at 1 hour after extubation) 1 hour
Secondary Adverse events Any adverse events in the PACU
Hypoventilation (respiratory rate < 10/minutes)
Hypoxemia (peripheral oxygen saturation < 94%)
1-24 hours
Secondary Given treatment according to patient and investigator Patient and investigator are asked to asses which treatment they believe was given 24 hours
Secondary 3 months follow-up Pain (NRS 0-10 in the surgical area and legs (left and right), analgesic consumption (opioids MME and secondary analgesics) and quality ogf life (Eq5D) 3 months
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2